The size of the Autoimmune Monoclonal Antibodies Market in the Asia Pacific is expected to reach USD 2712.95 million by 2027 from USD 1939.73 million in 2022, growing at a CAGR of 6.94% during the forecast period 2022 to 2027.
An increase in the prevalence of autoimmune disorders in the region and strategic collaboration and licensing partnerships between the company's safeties enhances the growth of the APAC autoimmune monoclonal antibodies market. Autoimmune disorders are conditions in which the body's immune system attacks healthy tissue. Autoantibodies are produced in autoimmune diseases, attacking the body's healthy cells. Autoimmune monoclonal antibodies are immunotherapy drugs that prevent healthy cells in the body from being damaged. In addition, the potential of mAbs in basic research and clinical applications has been enhanced because of advancements in mAb development methods. Therefore, the market is predicted to grow healthy throughout the forecast period, owing to a wide range of uses and efficacy in illness treatment.
Chronic and rare diseases are a key revenue growth driver in the autoimmune monoclonal antibody industry. For example, patients with cancer require long-term medicine and frequent delivery of mAb as directed throughout therapy. Along with disease prevalence, industry players' development efforts to create new products will bolster market growth. The market for autoimmune monoclonal antibodies is driven by the rising number of patients with severe arthritis and multiple sclerosis. In addition, the market for autoimmune monoclonal antibodies has grown due to a rise in the family history of immunological disease.
One disadvantage of mAb-based medications is that they are highly selective and have restricted targets. This is because they interact with cells rather than penetrate them. This has impacted the market to some extent. Another disadvantage of employing mAbs is that they must be injected, unlike small molecule medications. However, stringent FDA guidelines for approving new treatments may hamper the APAC autoimmune monoclonal antibodies market.
This research report on the APAC Autoimmune Monoclonal Antibodies Market has been segmented and sub-segmented into the following categories
By Source:
By Application:
By End-User:
By Country:
Due to a growth in the frequency of arthritis and related conditions and the availability of generic medications, Asia-Pacific is predicted to account for the most significant market share in the autoimmune monoclonal antibodies market in the future years. Asia-Pacific offers good opportunities for key players in the monoclonal antibodies market due to a growth in the number of initiatives and higher government investment for overall R&D of monoclonal antibody therapy and a rise in the number of products approvals. Furthermore, ongoing advancements in monoclonal antibodies, the availability of sophisticated healthcare systems, and significant growth in demand for advanced healthcare facilities are projected to boost the market. Furthermore, leading manufacturers' increased attention on increasing their geographical presence in growing Asia-Pacific countries to acquire high market share is predicted to fuel the region's monoclonal antibody market expansion. Cancer is a group of chronic diseases marked by uncontrolled cell proliferation. As the number of cancer patients rises, demand for monoclonal antibodies is predicted to rise, propelling the industry forward. According to GLOBOCAN, Asia Pacific saw a 45.8 percent increase in new breast cancer cases in 2018. According to the World Health Organization (WHO), approximately 18.1 million cancer cases and 9.6 million deaths worldwide in 2018.
KEY MARKET PLAYERS:
Companies playing a prominent role in the APAC Autoimmune Monoclonal Antibodies market include GlaxoSmithKline plc (U.K.), AstraZeneca plc (U.K.), F. Hoffmann-La Roche Ltd. (Switzerland), Bristol-Myers Squibb (U.S.), Johnson & Johnson (U.S.), Innovent Biologics, Inc. (China), Takeda Pharmaceutical Company Ltd. (Japan), Amgen Inc. (U.S.), Biogen Inc.(U.S.), and UCB Company (Belgium).
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 By Source
5.1.1 Murine
5.1.2 Chimeric
5.1.3 Humanized
5.1.4 Human
5.2 By Application
5.2.1 Systemic Lupus Erythematosus
5.2.2 Rheumatoid Arthritis
5.2.3 Multiple Sclerosis
5.2.4 Transplant Rejection/Graft Versus Host Disease
5.2.5 Others
5.3 End User
5.3.1 Hospitals/Clinics
5.3.2 Research Institute
5.3.3 Diagnostic Laboratories
6. Geographical Analysis
6.1 Asia-Pacific
6.1.1 Introduction
6.1.2 China
6.1.3 India
6.1.4 Japan
6.1.5 South Korea
6.1.6 Australia
7. Pipeline Product Analysis
7.1 Overview
7.2 Pipeline Development Landscape
7.3 Molecular Targets in the Pipeline
7.4 Clinical Trials
7.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target
7.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target
7.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target
7.5 Key Trends in Monoclonal Antibodies Development
7.5.1 Targeted Therapies
7.6 Promising Monoclonal Antibodies in Pipeline
7.7 Heat Map of Safety and Efficacy for Pipeline and Marketed Monoclonal Antibodies
8.Strategic Analysis
8.1 PESTLE analysis
8.1.1 Political
8.1.2 Economic
8.1.3 Social
8.1.4 Technological
8.1.5 Legal
8.1.6 Environmental
8.2 Porter’s Five analysis
8.2.1 Bargaining Power of Suppliers
8.2.2 Bargaining Power of Consumers
8.2.3 Threat of New Entrants
8.2.4 Threat of Substitute Products and Services
8.2.5 Competitive Rivalry within the Industry
9.Market Leaders' Analysis
9.1 GlaxoSmithKline plc (U.K.)
9.1.1 Overview
9.1.2 Product Analysis
9.1.3 Financial analysis
9.1.4 Recent Developments
9.1.5 SWOT analysis
9.1.6 Analyst View
9.2 AstraZeneca plc (U.K.)
9.6 Innovent Biologics, Inc. (China)
9.4 Bristol-Myers Squibb (U.S.)
9.5 Johnson & Johnson (U.S.)
9.6 Innovent Biologics, Inc. (China)
9.7 Takeda Pharmaceutical Company Ltd. (Japan)
9.8 Amgen Inc. (U.S.)
9.9 Biogen Inc.(U.S.)
9.10 UCB Company (Belgium)
10.Competitive Landscape
10.1 Market share analysis
10.2 Merger and Acquisition Analysis
10.3 Agreements, collaborations and Joint Ventures
10.4 New Product Launches
11.Expert Opinions
11.1 Market Outlook
11.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
Talk to our analyst and get customised report done according to your research needs
Check if you can avail any discount. Submit your details and our team will get back to you.
Request to avail a free sample report that reflects this market and its growth.
